| ID | Type | Location (GRCh37) | Location (GRCh38) | Length | GC content |
|---|---|---|---|---|---|
| hsa_CDYL_0008900 | Intron-Intron | chr6:4906511-4924979 | chr6:4906277-4924745 | 201 nt | 0.3831 |
| hsa_CDYL_0009000 | Intron-Intron | chr6:4908937-4912744 | chr6:4908703-4912510 | 250 nt | 0.4320 |
| hsa_CDYL_0009100 | Intron-Intron | chr6:4912246-4920371 | chr6:4912012-4920137 | 250 nt | 0.3040 |
| hsa_CDYL_0009200 | Intron-Exon-Intron | chr6:4912581-4936005 | chr6:4912347-4935771 | 164 nt | 0.5854 |
| hsa_CDYL_0009300 | Intron-Intron | chr6:4920093-4924979 | chr6:4919859-4924745 | 94 nt | 0.3723 |
| hsa_CDYL_0009400 | Intron-Intron | chr6:4924563-4924979 | chr6:4924329-4924745 | 122 nt | 0.4098 |
| hsa_CDYL_0009500 | Intron-Intron | chr6:4935091-4935748 | chr6:4934857-4935514 | 658 nt | 0.4179 |
| hsa_CDYL_0009700 | Intron-Exon-Intron | chr6:4935749-4936534 | chr6:4935515-4936300 | 786 nt | 0.5229 |
| hsa_CDYL_0009800 | Intron-Exon-Intron | chr6:4935749-4936541 | chr6:4935515-4936307 | 337 nt | 0.4599 |
| hsa_CDYL_0009900 | Intron-Exon-Intron | chr6:4935749-4936545 | chr6:4935515-4936311 | 257 nt | 0.4475 |
A study in humans demonstrated that the circCDYL is highly expressed in early stages of hepatocellular carcinoma, bladder cancers, and breast cancer [Misir et al. DOI:10.1038/s41418-022-00948-7]. In hepatocellular carcinoma, it promotes stem-like characteristics and tumor growth via the miR-328-3p/HIF1AN axis under hypoxic conditions [Huang et al. DOI:10.3390/cells11091381]. A study in mice demonstrated that the circCDYL is decreased in myocardial tissues and hypoxia myocardial cells, where it improves cardiac function after acute myocardial infarction [Sema Misir et al. DOI:10.1038/s41418-022-00948-7].